What do labels and trials say about triptorelin dosage and mixing for PCT?
Every vial at a glance.
| Vial | 2 mL of water |
|---|---|
| 3.75 mg | 1.875 mg/mL: 3.75 mg is over 1 mL |
| 11.25 mg | 5.625 mg/mL: 3.75 mg is 66.7 units |
| 22.5 mg | 11.25 mg/mL: 3.75 mg is 33.3 units |
The Trelstar label gives one injection of 3.75, 11.25 or 22.5 mg every 4, 12 or 24 weeks in advanced prostate cancer, mixed with 2 mL of sterile water, while the pack's searches of labels, regulator texts and trial records found no label or human trial of triptorelin for post cycle therapy.1
How the powder is supplied and mixed
The Trelstar label gives each vial with an injection kit holding a syringe of sterile water, a vial adapter and a needle.1 The labelled dose is the whole vial, and the pack's labels give neither a partial-vial volume nor a U-100 syringe mark; only the Decapeptyl IVF solution gives a concentration, 100 micrograms in 1 mL.2
| Product | Powder strength | Diluent in the kit |
|---|---|---|
| Trelstar (US label) | 3.75, 11.25 or 22.5 mg1 | Sterile water, 2 mL added to the vial1 |
| Triptodur (US label) | 22.5 mg3 | 2 mL sterile water3 |
| Decapeptyl SR 3 mg (UK summary) | 4.2 mg triptorelin as acetate, named 3 mg4 | 2 mL suspension vehicle4 |
The Trelstar label says to use sterile water and no other diluent, then shake the vial and adapter vigorously for 30 seconds.1 The Decapeptyl SR summary says to swirl the vial gently until a milky suspension forms.4 The Trelstar label says to give the suspension within 2 minutes of mixing, and the Triptodur label says to inject it immediately after mixing.13
Labelled dose, interval and route
In adults with advanced prostate cancer, the Trelstar label gives one injection every 4, 12 or 24 weeks for its 3.75, 11.25 and 22.5 mg strengths.1 The strengths are not additive and are chosen by the schedule wanted.1 For prostate cancer, the UK Decapeptyl SR summary gives one intramuscular injection every 4 weeks (28 days).4
The Triptodur label is for children aged 2 years and older with central precocious puberty.3 It gives 22.5 mg as a single intramuscular injection once every 24 weeks.3 The label gives no stepping for this product, and says another GnRH agonist that allows dose adjustment may be needed if the dose is not adequate.3
The Trelstar label gives a single intramuscular injection in either buttock, alternated periodically.1 The Decapeptyl IVF summary, for a ready-made solution used in women undergoing controlled ovarian hyperstimulation for assisted reproduction, gives a subcutaneous injection in the lower abdominal wall once daily, with a total treatment of 4 to 7 weeks as a rule.2
Trial doses, arm by arm
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| NCT01656161, prostate cancer | 22.5 mg subcutaneous, Day 1 and Day 1695 | 120 participants5 | To Day 3375 |
| NCT01467882, precocious puberty | 22.5 mg intramuscular, Day 1 and Day 1696 | 44 children6 | 12 months6 |
| NCT01020448, prostate cancer | One intramuscular 22.5 mg injection7 | 339 subjects7 | Up to month 67 |
| NCT00564850, precocious puberty | 11.25 mg intramuscular, day 1 and month 38 | 37 children8 | Screening to month 68 |
| Vuong 2016, oocyte donors | 0.2, 0.3 or 0.4 mg as an IVF trigger, not a course9 | One hundred sixty-five donors aged 18 to 359 | Not stated |
The Trelstar label reports randomized, active control trials of 277 men with advanced prostate cancer on 3.75 mg and 346 men on 11.25 mg, and a non-comparative trial of 120 men on 22.5 mg.1 Vuong 2016, in one hundred sixty-five oocyte donors, found no significant difference between 0.2, 0.3 and 0.4 mg used as an ovulation trigger in the number of mature oocytes and top-quality embryos.9
Triptorelin as PCT
The pack's searches of labels, regulator texts and trial records turned up no label or human trial of triptorelin for post cycle therapy. The Trelstar label is indicated for the treatment of advanced prostate cancer, and says its safety and efficacy have not been established in females.1 It also says that, based on mechanism of action, Trelstar may impair fertility in males of reproductive potential.1 After a single 3.75 mg injection in healthy men, the label describes testosterone peaking on Day 4 and falling to low levels by Week 4.1 For a mixed vial held longer than the labels' time limits, the searched texts give no stability data.
Storage
The Trelstar kit is stored at 20 to 25°C, and the Triptodur label gives 20 to 25°C with excursions to 15 to 30°C, and says do not freeze.13 The Decapeptyl SR summary says not above 25°C, in the outer carton, with a 3-year shelf life.4 The Decapeptyl IVF solution is a separate product, stored in a refrigerator and not frozen.2
Frequently asked questions
Can bacteriostatic water be used to mix triptorelin?
The Trelstar label says sterile water and no other diluent, and the searched labels give no statement on bacteriostatic water.1
References
- DailyMed. These highlights do not include all the information needed to use TRELSTAR safely and effectively. See full prescribing information for TRELSTAR. TRELSTAR ® (triptorelin pamoate for injectable suspension), for intramuscular use Initial U.S. Approval: 2000. 2026. dailymed.nlm.nih.gov
- Ethiopian FDA (Ferring SmPC copy). SUMMARY OF PRODUCT CHARACTERISTICS. efda.gov.et
- DailyMed. These highlights do not include all the information needed to use TRIPTODUR ® safely and effectively. See full prescribing information for TRIPTODUR. TRIPTODUR (triptorelin) for extended-release injectable suspension, for intramuscular use Initial U.S. Approval: 2000. 2025. dailymed.nlm.nih.gov
- electronic medicines compendium (UK). Decapeptyl SR 3mg powder and solvent for suspension for injection - Summary of Product Characteristics (SmPC) - print friendly - (emc). medicines.org.uk
- ClinicalTrials.gov. NCT01656161: Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer. 2015. clinicaltrials.gov
- ClinicalTrials.gov. NCT01467882: Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty. 2015. clinicaltrials.gov
- ClinicalTrials.gov. NCT01020448: Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer. 2015. clinicaltrials.gov
- ClinicalTrials.gov. NCT00564850: Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty. 2011. clinicaltrials.gov
- PubMed. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. 2016. pubmed.ncbi.nlm.nih.gov